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Patients
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A B S T R A C T
In this paper we present our experience with the Amplatzer septal occluder device, 
employed in 140 patients for percutaneous closure of atrial secundum defect (ASD), 
from October 2002 to February 2006. The age of patients ranged between 5.3 and 
70 years, median 21.9 years. Procedure time ranged between 25 and 240 minutes, 
median 60 minutes; fluoroscopy time ranged between 3.5 and 45 minutes, median 12 
minutes. Transoesophageal echocardiography was used to monitor the implantation 
procedure. The size of the selected device was 1 to 2 mm larger than the stretched di-
ameter of the defect and ranged between 6-40 mm. Two devices have been implanted 
in two patients. Serious procedure related complications (embolization and perfora-
tion of the left atrial wall) occurred in two cases. At follow up (10 days to 3.4 years, 
median 2.3 years) complete closure was documented in 97% of this patient group. 
Unrecognized during implantation, but detected after release, small additional defect 
with trivial residual shunt was documented in 4 patients. A young critically ill patient, 
cyanotic due to right-to-left shunt, with complex congenital heart disease developed 
a brain abscess three months after implantation. In conclusion, percutaneous ASD 
closure with use of the Amplatzer device in this patient cohort was highly successful 
with a low complication rate.
I N T R O D U C T I O N
The first nonoperative closure of atrial secundum defect (ASD) was performed by 
Noel L. Mills and Terry D. King in a 17-year old female patient on April 8, 1975 [1,2]. 
In the following years (1983) Rashkind developed a Clamshell device [3]. There was 
little interest in this clinical field and the trials with the “Clamshell Device” had been 
discontinued because of arm fractures. From the late 1980s until the mid 1990s E. B. 
Sideris (“Buttoned Device”) [4] and Babic [5] (“ASDOS”) kept the ideas of King & 
Mills alive while G.S. Das developed the first self-centering device (“Angel Wings”) 
[5-7]. Clinical trials with ASDOS and AngelWings have stopped because of compli-
cated technology and risk of perforation. Since the pioneering works of King & Mills 
marked improvements in devices and delivery systems have been achieved.
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Device ASD closure is now widely practiced and has re-
placed surgical ASD closure in many centers. Improvements 
in design have made the devices retrievable, and reduction in 
the size of the introduction systems allows interventional treat-
ment even in young patients. Different types of device are in 
widespread use, and new devices are being introduced. While 
the patch type occlusion device—represented by the Cardi-
oSeal, or its modification, the StarFlex [8,9] occluder (NMT 
Medical) and the Helex-device [7] (Gore) mimics surgery by 
placing a patch over the ASD, the self centering Amplatzer 
septal occluder [6,8], (AGA Medical Corporation) offers a 
different approach by stenting the interatrial communication. 
This unique technique makes it possible to close even up to 40 
mm large defects, while the inability to close such large defects 
remains a limitation of the patch type devices.
Since the first clinical trials with the Amplatzer septal 
occluder in 1995 and 1997, there have been many reports of 
excellent early follow up results after ASD closure with the 
Amplatzer occluder [6-12]. We now report our own clinical 
experience and short-midterm results with this device in pa-
tients who have presented with ASDs in our center.
P A T I E N T S - M E T H O D S
Between October 2002 and February 2006, 206 consecu-
tive patients with a significant ASD, demonstrated by initial 
transthoracic echocardiography (TTE), were considered for 
transcatheter closure with the Amplatzer septal occluder. A 
total of 156 patients underwent cardiac catheterization, and 
140 patients had successful transcatheter ASD closure with 
the Amplatzer device.
Routine examination before catheterization included a 
standard ECG, a chest x ray, blood tests and TTE (Figure 
3A). Magnetic resonance imaging (MRI) (Figure 3B), trans-
esophageal echocardiography (TEE), Valsalva maneuver and 
contrast injections were performed in selected cases.
We followed the manufacturer’s recommendation for 
echocardiographic exclusion criteria if the patient presented 
in TTE or TEE a distance of less than 5 mm from the rim of 
the defect to the atrioventricular valves, the coronary sinus, 
or the right upper pulmonary vein. After ASD closure the 
patients remained in the hospital for one night, and received 
heparin (partial thromboplastin time ≥50-60 seconds) for 14-
18 hours, followed by aspirin 2-3 mg/kg/d or and clopidogrel 
75 mg/d for six months. In the stroke group and in cases with 
coagulation disorders warfarin or acenocoumarol were given 
for six to twelve months. Before discharge an ECG, a biplane 
chest x ray, and a TTE examination were performed. Follow 
up examinations including ECG were scheduled at 1, 3, 12, 
24, and 48 months after the procedure. The 3 and 12 month 
follow-up examination also included a 24 hour Holter ECG 
recording. In order to study the right ventricular-remodeling, 
MRI studies were performed in 32 patient 3-12 months before 
and after transcatheter closure.
The initial TTE (Figure 4) showed the location of the ASD, 
its septal rim, and its diameter and also enabled us to measure 
the length of the interatrial septum in the four chamber view. 
These measurements were used to assess the feasibility of 
transcatheter closure with the Amplatzer septal occluder. The 
Amplatzer septal occluder is a self expanding, self centering, 
and repositionable double disc device constructed of a mesh 
of 72 nitinol wires. A 3-4 mm short cylindrical waist connects 
FIGURE 1. Patient age distribution.
FIGURE 2. Gender distribution: 49 were male (35%) and 91 
female (65%).
FIGURE 3. The ASD as depicted by TTE (A), and MRI (B) 
in two candidates for interventional therapy. Volume overload-
large right atrium and ventricle, central ASD with adequate 
rims.
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the two round discs. Basically, the Amplatzer septal occluder 
stretches and stents the ASD. Thus the diameter of the waist 
has to correspond to the so called “stretched” diameter of the 
ASD, determined by a balloon sizing catheter. Additionally, 
polyester fibers are sewn into the device promoting thrombosis 
and complete defect occlusion. Twenty seven different sizes 
with waist diameters from 4-40 mm are available. For devices 
between 4-10 mm, the left atrial disc is 12 mm larger than the 
waist and the right atrial disc is 8 mm larger. For bigger devices 
the left atrial disc is either 14 mm larger than the waist (waist 
diameter 11-30 mm) or 16 mm larger than the waist (waist 
diameter 32-40 mm).
For transvenous implantation of the Amplatzer occluder, 
the manufacturer provides a loader, a delivery cable, and a 6-12 
French long sheath. Before loading the device into the long 
sheath it is connected to the delivery cable by a microscrew 
fixed to the right atrial disc. In the catheterization laboratory 
a biplane transesophageal echocardiogram (TEE) was done 
under general anesthesia (in all except one) to evaluate the size 
and location of the defect and its margins. Vascular access was 
obtained from the femoral vein, and heparin (100 IU/kg max 
9000 IU, ACT ≥250), and antibiotics (cefazolin) were given; 
two cases with coagulation disorders received danaparoid 
sodium (Orgaran). After making a complete haemodynamic 
evaluation, an anomalous pulmonary vein connection was 
excluded by angiocardiography in the pulmonary artery. The 
“stretched” diameter of the ASD (Figure 5A, 5B and 5C, 5D, 
5E: 2 defects, 2 balloons) was measured using a Numed or Am-
platzer sizing balloon. A device with a waist diameter similar 
to, or in large defects up to 2 mm bigger than, the stretched 
ASD diameter was chosen. After introducing the long sheath 
over the exchange guide wire into the left upper pulmonary 
vein, the device was inserted and deployed under fluoroscopic 
and TEE guidance, as described in previous publications. A 
secure and stable position of the occluder within the defect 
was checked by a push-pull maneuver (Minnesota wiggle). The 
device and adjacent structures were then examined by TEE 
to ensure that there was no encroachment of the device on 
the atrioventricular valves or the right pulmonary veins. After 
releasing the device from the cable by unscrewing it (Figure 7), 
a final TEE examination was undertaken to demonstrate the 
position of the device and any residual shunting (Figure 8).
R E S U L T S
Between October 2002 and February 2006, 156 patients 
underwent cardiac catheterization, and 140 patients had suc-
cessful transcatheter ASD closure with the Amplatzer device. 
Their ages ranged from 5.3 to 70 years (median 21.9 years), 49, 
35%, were male, 91, 65% female (Figure 1and 2 for age and 
gender distribution). The majority (85%) of the patient group 
showed a simple, single centrally located fossa ovalis ASD on 
echocardiographic examination, while 15% of the cases had 
multiple or fenestrated defects, an additional septal aneurysm, 
inferior extension of the defect towards the atrioventricular 
valves or coronary sinus. Nine patients suffered from stroke. 
One patient had a significant residual ASD after previous 
FIGURE 4. TEE with the location of the ASD, its septal rim, 
and its diameter The ASD and the rims must be exactly mea-
sured. Only patients with a distance of more than 5 mm (rim) 
of the defect to the superior vena cava, atrioventricular valves, 
the coronary sinus, or the right upper lobe pulmonary vein are 
candidates for interventional treatment. Device closure of infe-
rior and anterior defects with rims <5 mm or oversized devices 
could compromise the mitral valve or obstruct the SVC, IVC or 
the pulmonary vein. ASD= atrial septal defect; IVC= inferior 
vena cava; SVC= superior vena cava.
FIGURE 5. ASD sizing procedure: The waist of the balloons, 
A: 39 mm and B: 10mm respectively, clearly indicates the 
“stretched” diameter of the atrial septal defects. C, D, E:11-
year-old patient with two large defects. The waists of the bal-
loons are 16 mm and 26 mm respectively.
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CardioSeal implantation, two devices were implanted in two 
patients, one during the same session.
On TEE, the maximum defect diameter varied between 
4-38 mm, while the balloon stretched diameter (Figure 5) 
varied between 6.5-40 mm. Implanted devices had a waist 
diameter similar to or slightly larger than the stretched di-
ameter implanted, ranging between 6-40 mm (Figure 6). The 
procedure time varied between 45-175 minutes (median 60 
minutes) and the fluoroscopy time between 3.5-65 minutes 
(median 12 minutes), with a tendency to shorter procedural 
and screening times after the initial learning curve. In 55% 
of the patients with an ASD, large devices of 20-40 mm were 
employed and devices <10 mm were used in only 4 patient. 
Two 40 mm devices were implanted.
Nine of 10 patients with multiple or fenestrated defects 
were treated with a single device, while in one patient two 
devices were implanted simultaneously through separate 
delivery systems. Defects with an additional septal aneurysm 
were successfully closed by catching the aneurysm during the 
process of configuring the right atrial disc (or using the cribi-
form occluder in two cases), resulting in a firm compression 
of the aneurysm towards the atrial septum.
At the time of cardiac catheterization, nine patients were 
excluded after TEE examination, as follows: inferior-posterior 
defects and no rim near the orifice of the inferior caval vein, 
defects that were very near the coronary sinus, large defect that 
was near the-entrance of the superior caval vein, with only a 
small rim towards the right pulmonary veins, two symptomatic 
children had a defect diameter of more than 36 mm on TEE 
and interatrial septum length of only 46 mm.
Seven further patients were excluded after initial angiog-
raphy, hemodynamic evaluation, balloon sizing of the defect, 
or trial of device placement. Three of these showed drainage 
of the right pulmonary veins into the superior cava vein. One 
symptomatic adult had additional coronary disease. After bal-
loon sizing four patients were excluded; three of these had 
large inferior-posterior defects with a stretched diameter of be-
tween 26 mm and more than 36 mm and an insufficient margin 
towards the inferior caval vein. Despite repeated trials, device 
placement failed in three cases because of insufficient inferior 
margins (1) or large defects with a floppy septum (2).
On color flow Doppler, residual shunting—including 
foaming through the wire mesh of the device—was seen in 
about 80% of cases directly after implantation. By the time 
of discharge, 24 hours after ASD closure, the rate of residual 
leakage had decreased to 15%. During further follow up exam-
inations (10 days to 3.4 years, median 2.3 years) the complete 
closure rate has reached 97-98%. A trivial residual shunt is 
still present in 4 patients. 2/4 patients had unrecognized small 
additional defects during initial TTE and implantation. The 
third and fourth patient of this subgroup had small defects 
near the superior and inferior vena cava respectively.
After transcatheter closure of the interatrial communi-
cation in adults a reduction of migraine or headache was 
observed. In this small group of patients (retrospectively 
analyzed) migraine disappeared completely in 60%, while 
40% described improvement in symptoms.
There were 3 major procedure related complications at 
our institution. The first was an embolization in a patient with 
small inferior rim directly after release. In this case the device 
embolized just above the mitral valve. Although the child was 
stable and asymptomatic device transcatheter retrieval was not 
attempted. The device was retrieved surgically and the ASD 
closed by patch. The second procedure related complication 
was a perforation of the left atrial posterior wall with the 
extra stiff madrain which led to 5 mm pericardial effusion. 
The procedure was stopped; there were no sequelae of this 
event. A significant event occurred 3 months after a success-
ful and uneventful closure of a fenestrated Fontan with an 
Amplatzer occluder in a young cyanotic patient with complex 
congenital heart disease. This 8-year old girl developed fever 
and headache. Computed tomography showed a brain abscess. 
FIGURE 6. Occluder diameter: 55% of patients with an ASD 
were closed with large devices of 20-40 mm, 42% with devices 
10-20 mm and only 3% with devices <10 mm.
FIGURE 7. Lateral view of an implanted Amplatzer septal oc-
cluder (16 mm) during and directly after implantation.
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On TTE no unusual finding, thrombus formation or residual 
shunt were seen. After operation and antibiotic therapy for 
4 weeks, patient’s symptoms completely resolved without any 
neurological sequelae (this event confirms our recommenda-
tion of life long observation after device implantation).
Relevant cardiac dysrhythmias associated with trans-
catheter closure occurred in one case. A 38-year old man 
developed recurrent atrial flutter three months after uncom-
plicated ASD closure with a 36 mm occluder. In this patient 
long term maintenance of sinus rhythm was achieved first 
with propafenone. Six months later the patient decided to 
stop his medication. Recurrent atrial flutter led us to plan 
and perform ablation of the right circuit. It was not necessary 
to study the left atrial wall or the pulmonary vein region. No 
patient complained about amaurosis fugax or blurred vision 
after the procedure. No other early or late complications such 
as pericardial effusion, compromise of intracardiac structures, 
late device embolization, cerebral embolism or endocarditis-
occurred during follow up.
D I S C U S S I O N
The ease of implantation and the superior success rate of 
ASD closure [12] with the Amplatzer septal occluder has led 
to the widespread employment of transcatheter occlusion of 
ASD and has replaced routine surgical closure in many centers 
[8,10,12]. There is no doubt that this success rate is a result of 
the design of the Amplatzer occluder, which is completely dif-
ferent from the patch type systems. The most important aspect 
is that the device’s waist between the left and right retention 
discs is a stent, resulting in self-centering within the defect. 
Thus, the Amplatzer occluder requires only a small rim around 
the defect for firm cross clamping by the retention discs. The 
unique design, using a nitinol mesh, overcomes many of the 
limitations of other ASD occlusion devices. Although large 
delivery systems up to 12 French are necessary, the Amplatzer 
septal occluder is retrievable without damaging the device, 
the device is self-centering, and occluders large enough to 
close defects of up to 40 mm in diameter are available. Other 
devices can only close defects of up to 20 mm diameter, which 
excludes many patients with larger defects.
TTE and TEE have proved to be very important tools for 
the exact anatomical delineation of the defect within the atrial 
septum [9,11-13]. As it is difficult to examine defects in older 
patients using TTE, inspection of the exact nature of the sep-
tal rim near other cardiac structures like the atrioventricular 
valves, the right pulmonary veins, or the inferior caval vein 
must be carried out with TEE before catheterization. Defects 
near the entrance of the inferior caval vein, should easily be 
identified by TTE in the pediatric age group.
The manufacturer’s recommended exclusion criterion is 
an ASD with a rim to the atrioventricular valves of less than 
5 mm [6,8,10,11]. Device closure of these inferior and ante-
rior defects could compromise the mitral valve. None of our 
patients with a rim of <6 mm developed mitral regurgitation. 
Similarly, the device can obstruct the orifice of the right pul-
monary veins in rare cases with a more superior and posterior 
defect location; this did not happen in our patients [8,11]. 
The possibility of the retention discs impinging on sensitive 
structures is particularly pertinent when dealing with small 
children or using large or oversized devices [8,11,12]. An ad-
ditional consideration is the length of the interatrial septum, 
which should be sufficient to accommodate the device [13].
TEE is also very important to ensure the correct position-
ing of the device before and after its release [8,11,13]. This is 
critical in the closure of large defects because the left atrial 
retention disc in bigger devices is relatively small in relation to 
the waist diameter. Because of this, its cranial portion tends to 
slip through the defect, and this may result in early or even late 
embolization of the device [13,14]. Furthermore, TEE is useful 
in directing the catheter through the largest communication 
in cases of multiple ASDs, and helps to reduce the screening 
FIGURE 8. TEE after implantation. The device was inserted 
and deployed under fluoroscopic and TEE guidance. Occluder 
and adjacent structures were then examined to ensure that 
there was no encroachment on the atrioventricular valves or the 
right pulmonary veins.
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time significantly [8,12,13]. It has even been suggested that 
ASD closure with the Amplatzer occluder can be carried out 
under TEE guidance alone [13,15].
Cobra head malformation of the Amplatzer septal oc-
cluder is sometimes difficult to overcome and may prolong 
the procedure [8,15]. While it occurred more often in the 
past with the first generation of Amplatzer devices, it still 
may happen, particularly if there is not enough space for the 
configuration of the left or right atrial disc within the left or 
right atrium in a small patient. This can cause twisting of the 
occluder during deployment owing to the leading edge of the 
device catching on the atrial free wall or the appendage.
A point of criticism of the Amplatzer septal occluder is that 
it sometimes appears bulky after implantation. This may be 
the case if, owing to inaccurate balloon sizing, a device with 
too large a stent is implanted. “Mushrooming” of the retention 
discs can then occur [15]. This is more likely when the stent 
is compressed so that the waist measured on fluoroscopy is 
more than 4 mm smaller than the nominal diameter of the 
stent [8,11-13,15]. Inaccurate balloon sizing is now rare owing 
to the introduction of new static sizing balloons; overestima-
tion of the defects mushrooming has become rare. Inaccurate 
sizing of the ASD is not the only cause of malformation of 
the implanted occluder; it could also happen if the diameter 
of the retention discs exceeds the length of the interatrial 
septum [11,14]. To avoid such a deformation and any potential 
obstruction of cardiac structures, this experience led us to be 
making an initial assessment of the interatrial septal length 
from the four chamber view on TTE as an important body 
weight dependent variable. In cases of large ASDs the septal 
length should not be exceeded by the diameter of the left disc 
occluder. In addition to echocardiographic follow up studies, 
32 patients also had an MRI study, which showed no evidence 
of any device related obstruction. From this limited experi-
ence, we conclude that MRI, in addition to echocardiography, 
will allow non-invasive follow up examination and probably 
has the potential to replace x ray for ASD closure in the fu-
ture [16]. In the future this method may be used also as an 
indicator of endothelialization of the device and it could be 
interpreted as a potential advantage that protects the integrity 
of the occluder [8,16].
The high percentage of previously reported residual leaks, 
which were up to 53% with the first generation of patch type 
devices has improved over the years but is still 20% at one year 
after the procedure, as reported recently in the multicenter ex-
perience using CardioSeal and StarFlex devices [13,15]. With 
the Amplatzer occluder we observed a complete occlusion rate 
of 97-99% during follow up, with only 4 patients still showing 
a trivial shunt on color flow Doppler. Though these residual 
leaks are trivial, it seems of interest that with one exception 
they occurred only in patients who had an additional ASD or 
defects with an additional septal aneurysm.
Whether or not one should use general anesthesia for spe-
cific interventional procedures may be a question of economics 
for some institutions or simply a question of the availability of 
anesthetic coverage [6,8,9,11,15]. On the other hand, unlike 
adult patients, a child will not tolerate the TEE probe without 
heavy sedation (for example, with propofol or ketamine) and 
continued spontaneous breathing, which may carry a risk of 
air embolism through the long sheath, owing to the negative 
intrathoracic pressure. In order to avoid irreversible myocar-
dial or cerebral damage or even death after air embolism to 
the left heart, we now perform all interventional ASD closures 
under general anesthesia with mechanical ventilation.
Until now, we have seen only one patient who developed ar-
rhythmias after ASD closure with the Amplatzer occluder. In 
the case of a 38-year-old man with atrial flutter, development 
of the arrhythmia seemed to be the result of long standing 
right atrial volume overload and dilatation rather than being 
device related. In our patient group sudden onset of complete 
atrioventricular block did not occur.
C O N C L U S I O N S
Transcatheter closure of atrial septal defects has become 
a routine procedure in many countries of the world. It spares 
many patients cardiac surgery and has proven efficacy in 
long-term studies. Device improvements have resulted in a 
continuous reduction of complications and of residual shunt 
frequency. Although lifelong observation is required, this 
single center experience with the Amplatzer septal occluder 
shows good closure results for the majority of the ASD pa-
tients.
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